Roche's Avastin fails in Phase III advanced stomach cancer trial
This article was originally published in Scrip
Executive Summary
Avastin (bevacizumab) failed to extend the lives of patients with inoperable or advanced stomach (gastric) cancer when used with chemotherapy compared with chemotherapy alone, Roche (Genentech) reports with top-line Phase III AVAGAST trial results.